Evotec SE header image

Evotec SE

EVT

Equity

ISIN DE0005664809 / Valor 505433

Xetra (2025-11-14)

EUR 5.29-2.97%

Evotec SE
UMushroom community rating:

4.29 7 votes No rating yet

NegativeNeutralPositive

About company

Evotec SE is a global drug discovery and development partnership company headquartered in Germany, specializing in providing integrated solutions to the pharmaceutical and biotechnology industries. The company leverages its extensive expertise in areas such as medicinal chemistry, biology, and data science to support the development of new therapeutics across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. Evotec collaborates with a diverse range of partners, including major pharmaceutical companies, biotech firms, and academic institutions, to advance innovative drug candidates from early discovery through clinical development. In the first quarter of 2025, Evotec reported progress in strategic partnerships and the implementation of initiatives aimed at achieving sustainable and profitable growth, reinforcing its position as a key player in the biopharmaceutical landscape.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-38.7%1Y

-72.2%3Y

-79.1%5Y

Performance

69.3%1Y

65.6%3Y

58.0%5Y

Volatility

1090 M

Market cap (USD)

1,519,577

Daily traded volume (Shares)

8.73 / 8.45

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.29

7 votes

Performance:

4.29

Innovation:

4.29

Society:

4.00

Nature:

3.86

Meret Jaggi

Switzerland, 30 May 2022

Oliver Moon

Switzerland, 30 May 2022

German biotech/ pharma company. Decent upside potential. Analyst buy. Good performance history. Seems good to me.

Atanas WI Atanasov

United Kingdom, 30 May 2022

EQUITIES OF THE SAME SECTOR

Siegfried Holding Ltd

Siegfried Holding Ltd Valor: 1428449

Annual Return

-50%0%+50%

Risk level

110

-1.45%CHF 75.00

Concentra Group Holdings Parent Inc

Concentra Group Holdings Parent Inc Valor: 136105334

Annual Return

-50%0%+50%

Risk level

110

-1.67%USD 19.42

Ambea AB

Ambea AB Valor: 36138415

Annual Return

-50%0%+50%

Risk level

110

0.39%SEK 128.30

Nano-X Imaging Ltd.

Nano-X Imaging Ltd. Valor: 56410599

Annual Return

-50%0%+50%

Risk level

110

1.71%USD 2.97

Vimian Group AB

Vimian Group AB Valor: 111662981

Annual Return

-50%0%+50%

Risk level

110

-0.97%SEK 30.64

L'Oreal S.A.

L'Oreal S.A. Valor: 502805

Annual Return

-50%0%+50%

Risk level

110

-0.03%EUR 354.88

Estee Lauder Companies Inc

Estee Lauder Companies Inc Valor: 99350

Annual Return

-50%0%+50%

Risk level

110

-1.94%USD 88.18

COSMO Pharmaceuticals N.V.

COSMO Pharmaceuticals N.V. Valor: 32590356

Annual Return

-50%0%+50%

Risk level

110

-0.31%CHF 65.10

Basilea Pharmaceutica Ltd, Allschwil

Basilea Pharmaceutica Ltd, Allschwil Valor: 1143244

Annual Return

-50%0%+50%

Risk level

110

-1.06%CHF 46.85

SOLVENTUM CORP

SOLVENTUM CORP Valor: 133635906

Annual Return

-50%0%+50%

Risk level

110

0.58%USD 75.66

SIX

FactSet

Clearbit

Logos provided by Clearbit